Abstract:Atrial fibrillation (AF) is an increasingly common arrhythmia that now stands at epidemic proportion, with more than 2.3 million people affected in the USA and over 4.5 million people affected in Western Europe. AF is an expression of underlying heart disease and is increasingly associated with hypertension, congestive heart failure, and ischemic heart disease. It is also a progressive disease secondary to continuous structural remodeling of the atria, which relates to AF itself, to changes associated with aging and to progression of the underlying heart disease. Traditionally, AF has been addressed only after it has already presented with pharmacological and nonpharmacological therapies designed for rhythm or rate control (secondary prevention). Although secondary prevention is the most feasible approach at present, the concept of primary prevention of AF with therapies aimed at preventing the development of substrate and correcting the risk factors for AF has emerged as a strategy, which is likely to produce a larger effect in the general population. Recent experiments provided new insights into AF pathophysiology, which generated background for new mechanism-based therapies. Agents targeting inflammation, oxidative injury, atrial myocyte metabolism, extracellular matrix remodeling, and fibrosis have theoretical advantages as novel therapeutic strategies. In this respect, drugs that are not traditionally antiarrhythmic such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, aldosterone antagonists, statins, and omega-3 polyunsaturated fatty acids have shown an antiarrhythmic potential in addition to any treatment effect on the underlying disease. These agents are thought to have an advantage of targeting both the occurrence and progression of the substrate for AF, thus, providing primary and secondary prevention of the arrhythmia. Although first experimental and hypothesis-generating small clinical studies or retrospective analyses have been encouraging, several larger, properly designed, prospective trials have not confirmed earlier observations. This review provides a contemporary evidence-based insight into the possible preventative and reverse remodeling role of statins and polyunsaturated fatty acids in AF.

Statins and Prevention of Atrial Fibrillation in Patients with Heart Failure.

Update on the efficacy of statins in primary and secondary prevention of atrial fibrillation

Statins and Prevention of Stroke in Patients with Non-Alcoholic Fatty Liver Disease

Statin Use and Development of Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Studies

Statin therapy in the prevention and treatment of atrial fibrillation

Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance

Statin Therapy is Associated with a Lower Risk of Heart Failure in Patients with Atrial Fibrillation: A Population‐Based Study

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

Independent and Joint Association of Statin Therapy with Adverse Outcomes in Heart Failure Patients with Atrial Fibrillation Treated with Cardiac Resynchronization Therapy.

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Current Evidence and Perspectives

Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial

Usefulness of Statins Pretreatment for the Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Effect of Statin Therapy on Arrhythmias

Statin administration improves vascular function in heart failure with preserved ejection fraction

Prevention of atrial fibrillation after cardiac surgery by preoperative use of statins: a meta analysis

Effect of Statin Therapy on Heart Failure

Statin Use and Stroke Rate in Older Adults With Atrial Fibrillation: A Population-Based Cohort Study

Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction

Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials.

Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during the postmyocardial infarction remodeling process.